A phase 2 trial looking at the efficacy and safety of 8–12 weeks of afatinib prior to surgical resection in patients with EGFR mutant + NSCLC enrolled 47 participants with stage IIIA-C disease. Here, EGFR is linked to non-small cell lung carcinoma.